Marwah Medicine

3 tips
Medicine, NEET PG

3 Tips to help you tackle Multiple Choice Exams

Multiple choice exams can be quite tricky, especially when you’re in a race against time. However, with a bit of strategy and planning, you can take on multiple choice questions with confidence and ease. Here are three tips to help you improve your performance in MCQ exams. Eliminate the Wrong The smartest way to tackle Multiple Choice Exams is by eliminating the obviously wrong options first. A typical MCQ has 3 wrong options and 1 correct option. It is way easier to detect the wrong answers than figuring the right one. Most MCQs are set up in such a way that two choices are straight out wrong, one is there to trick you, and one is correct. When you narrow down your choices, you greatly increase your chances of choosing the right answer. It has been rightly said that MCQ exams have more to do with eliminating wrong options than finding the right ones. Always be Extra Careful When you’re giving a lengthy Multiple Choice Exam your brain tends to get tired and you end up making careless mistakes. MCQ exams are notorious for tricking you into making mistakes by giving you trick options which, at first, may appear to be the correct answer. Try to stay alert, and double-check your entire paper for silly mistakes and trick options. Going through the paper one last time before submission is the best way to deal with careless mistakes that may initially go unnoticed. Make Smart Guesses If there isn’t any negative marking, just make an educated guess. The good thing with MCQs is that there multiple ways to reach the correct answer. For example, if you’re struggling to remember the exact answer, try recalling related information instead. It’ll eventually lead you to the answer. Also pay close attention to words like always, not, never, etc. Conditional words are often used to trick and confuse you so tread with caution whenever you come across any such words. When you’re faced with ‘all of the above’ or ‘none of the above’ choices, do not choose ‘all of the above’ if you’re confident that even one of the options is incorrect. Similarly, if you’re sure that at least one of the options is correct, do not go for ‘none of the above’.

5 way to overcome
Medicine, Medicine classes

5 Ways to Overcome the Fear of Failing in Exams

Have you ever been so afraid of failing at an exam that you just skipped it altogether? Fear of Failure is paralyzing. It leads to missed opportunities, inactivity, and low self-esteem. But don’t let the fear of failing an exam take over your life. Here are 5 proven ways to help you overcome this fear and create a healthier mindset. Identify the Root Cause of your Fear Examine your negative beliefs. Where does your fear of exams originate from? Take some time, sit down and introspect. Ask yourself the tough questions. Is the fear legit? How did you develop this fear? Is it making your life better or worse? And finally, what is the real cause behind your fear of failing exams? Once you figure out the real reason behind your fear of failure, you’ll realize that it sounds silly and you’ve fretting over nothing. Examining your negative beliefs is not easy, and requires a lot of courage. But it is definitely worth doing if you want live your life to the fullest. Remind yourself that Failure is Temporary Failure may feel permanent but it is nothing more than a temporary setback. The consequences of failure are never as bad as you imagine. Always remember that failing an exam is nothing more than a road bump. It is not the end of your life. Instead try to look at failure as feedback. When you fail an exam, you get to analyze where you went wrong which helps you prepare better for the next attempt. Overcome all-or-nothing Mindset All-or-nothing thinking or perfectionism is away thinking that pushes you towards unrealistic goals. Perfectionism is often seen as a strength, but being too much of a perfectionist can sometimes lead to self-defeating thought patterns. Too much perfectionism may lead to anxiety, fear of failure, and low self-esteem among other mental health issues. If you’re struggling with perfectionism, start with slowly challenging your behavior. List down things you believe should be done perfectly. Next write the reasons why you believe that activity must be perfect. And at last, write down the consequences if things don’t turn out as planned. When you write things down, you’ll be able to see through your negative beliefs and tackle them with better understanding. Work towards building a Healthy Self-Esteem When you have healthy self-esteem, you don’t see failure as a dead end but as a stepping stone to success. Work of shifting your perspective. Failure is inevitable. Even the most brilliant brains have faced failure. And who said failure is a bad thing? Failure is actually a blessing in disguise. Failure, not a success, teaches you lessons worth learning Exams. Welcome failure. Befriend your fears. Only then can you overcome them. Start Exercising and Meditating Join a gym. Go on a run. Work-out. Exercise releases endorphins which are natural painkillers, and help you combat stress in a much healthier way. Meditation is a great way to calm your mind and prepare yourself to face your fears with courage. When you meditate, you free your mind from anxious thoughts and become much more aware of yourself and your surroundings. Your breathing slows down, your mind stops racing and your pulse rate drops to a healthier level.

Artboard 3
Medical, Medicine classes, NEET PG

3 ways to overcome afternoon drowsiness for Doctors preparing

For NEET PG entrance / NEXT examination While it is common for small children to take afternoon naps, we grown-ups cannot afford the same luxury. Research shows it is quite natural to experience drowsiness and lethargy during in the afternoon, around 8 hours after waking up. Drinking an extra cup of coffee may sound tempting, but it is certainly not the healthiest way to stay awake. While these hacks may help you temporarily ward off afternoon drowsiness, you may want to ensure there’s no underlying medical condition at play. Most young people don’t realize that this drowsiness can be symptom of iron or nutrient deficiency, insulin resistance or obstructive sleep apnea. No harm or shame in getting yourself evaluated rather than using quack remedies to ward off sleepiness. Today, I’m going to share with you 3 healthy ways to combat afternoon drowsiness and re-energize your body. Take a Power Nap Another great way to combat afternoon sluggishness is take a quick 20-minute power nap. Research proves that 20 minutes of afternoon sleep is way more restful than 20 minutes of extra sleep in the morning. Don’t look at FaceBook or Whatsapp during lunch which we normally do. That just saps our brain further. Say No to Canteen Food which is greasy and unhealthy. Either cook your self or order from a healthy restaurant. Processed food digests quickly, messes with your blood sugar levels, and leads to low energy levels. As someone struggling with afternoon sluggishness, you should avoid processed food at all costs. Instead opt for healthy, energizing meals which are rich in iron, lean protein and complex carbohydrates, for example: leafy green vegetables, lean meat, whole grains etc.

etiquette tips
Etiquette, Medicine

Etiquette Tips for Practicing Doctors

Patient satisfaction has become of vital importance in today’s time. Following proper etiquette can make a big difference to how your patients view you.  If your patients feel valued and important, they’re more likely to trust you and come to you every time they require medical assistance. Take your time when talking to patients Patients often complain that their physicians don’t give them enough time or don’t give them their full attention. While this complaint might not be true, it is good etiquette to make the patient feel valued and important. As a doctor, you should pay full attention to what your patient is saying. Stop, listen and don’t interrupt. Look patients in the eye, give them quality attention. Use good listening skills like nodding, repeating what you have heard and paraphrasing the patient’s main concern. All of this will assure the patient that you care about his/her well-being. Never forget to Meet and Greet Always introduce yourself in a warm and friendly way. Smile at patients and look them in the eye. Start addressing patients by their names as soon as possible. But remember to be courteous. If the patient is your grandmother’s age, you won’t go addressing her from her first name.  Instead use culturally accepted titles. Staff members, because of their hectic schedule, often forget to greet patients. As a doctor, it is your duty to remind staff members to practice good etiquette as well. Always keep the patient updated with what’s going on The patient must always know what is going on and the next step is. For example if you’re a dentist, you should always explain what is happening, what your next plan of action is, and how long it will take. If a patient is fully aware of what’s going on, he’s more likely to trust you and it will If the patient has been sitting in the waiting room for quite some time, send someone to check on him every now and then. Waiting for long periods of time isn’t easy but assurance from staff members can make a big difference. Always Dress Professionally Most doctors normally wear a white coat which helps differentiate them from staff members. This is good practice. Avoid street wear, flashy clothes or anything that may come off as too casual. Even though how you dress is in no way a judge of your abilities, unprofessional attire may give a poor impression to patients, and even lead them to distrust your credibility.

5 ways to overcome
Antibiotics, Medical, Medicine

5 Ways to Overcome Overthinking and self-criticism

For doctors who are programmed into doing so from the first year of medical college Overthinking is when you do excessive thinking but never take any real action. It leads to unneeded stress and creates problems that didn’t even exist in the first place. It robs the joy out of the present moment. 5 Ways to overcome overthinking and self-criticism And what’s worse is that once you spiral into overthinking, it becomes really hard to come out of its ugly trap. But today I’m going to share with you 4 ways that not only stop overthinking but also encourage self-reflection and problem-solving. 5 Ways to Overcome Overthinking and self-criticism 1. Always Note down Negative Thoughts Writing about your negative thoughts and emotions can be quite therapeutic. It slows down ruminating thoughts and helps you better analyze your situations. When you write down your worries, you may even find that you have been stressing unnecessarily over silly things. When sit down to write, start by asking yourself how you’re feeling, why you’re feeling that way and how can you work to change it. These questions will help you slow down your mind, focus on your situation, and think clearly for solutions. 2. Go for a run or do some squats Physical exercise is a proven way to fight stress and anxious thoughts. When you work-out, your body releases endorphins which are natural painkillers and mood enhancers. Even clinical trials have verified that physical exercise can help fight depression and anxiety. 3. Start Living in the Present Almost all overthinking is caused by living in a moment other than the present. Instead focus on what’s happening right now. Make every hour count by learning a new topic or solving more questions. Use Social media only for limited time daily. 4. Practice Meditation Research shows that even a few minutes of mediation every day can have a profound impact on your life. And you don’t even need to do anything intricate. Just close your eyes and focus on breathing slowly. 5. Start using a Calendar Most smartphones are now equipped with calendar apps (think google calendar) that help you manage your time efficiently. Using a calendar may, at the beginning, look tedious but it is the best way to organize your time. You can plan out which classes to attend, which subjects to dedicate more time to, and on which days you should appear for a GT.

Medicine classes

Commotio Cordis: When a Blow to the Chest Stops a Heart

The tragic death of Spanish footballer Jesús de Miguel—and the electrical accident every medical student should understand. The moment football stopped Ninety minutes of football. The scoreboard read 2–2. The match between CD Tenerife and FC Andorra was deep into added time on 2 November 2026 when striker Jesús de Miguel chased a loose ball near midfield. Goalkeeper Jesús Owono had raced out to challenge for it. The two collided; reports describe a forceful impact to de Miguel’s chest. He went down, medical staff rushed onto the pitch, and the match was abandoned. This was no longer about a result. De Miguel, 30, was taken to hospital after a reported cardiac arrest. His circulation was reportedly restored during emergency care, but his neurological condition later deteriorated. Tenerife announced his death at 8 a.m. on 3 November. The Spanish football community mourned him with tributes across stadiums. [1–3] Reports citing preliminary forensic findings point to accidental chest trauma; some subsequent reporting specifically raised commotio cordis. The complete forensic record and rhythm documentation have not been made public. It would therefore be inaccurate to call the precise arrhythmic mechanism definitively proved. But the case offers an urgent lesson in how chest trauma can cause sudden cardiac arrest. [2–4] A strange possibility: the heart may be structurally normal Most of us associate sudden cardiac death in an athlete with an abnormal heart: hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, coronary anomalies or an inherited channelopathy. Commotio cordis is different. It is an abrupt, usually ventricular-fibrillation cardiac arrest triggered by nonpenetrating impact over the precordium during a brief electrically vulnerable phase of the cardiac cycle. The classic case has no pre-existing structural heart disease to explain the arrest. [5–7] Think of it this way: the chest receives a mechanical blow, but the catastrophe is primarily electrical. A heart need not rupture, tear or even show major visible damage for a lethal arrhythmia to start. Nor does the person have to be an elite athlete. [5,6] The few milliseconds that matter: why the T wave is the culprit A normal heartbeat is a carefully timed electrical sequence. The QRS complex represents ventricular depolarisation. The T wave represents ventricular repolarisation. During a narrow interval around the early or ascending portion of the T wave, ventricular tissue is particularly vulnerable to a premature electrical disturbance. If a blow arrives directly over the heart at just that moment, sudden myocardial deformation can activate mechanosensitive ion channels. The resulting abnormal current may trigger premature ventricular excitation and degenerate into ventricular fibrillation (VF). This interaction is called mechano-electric coupling. Experimental models demonstrate an especially narrow vulnerable interval, about 15 milliseconds in one well-studied animal model; clinical descriptions commonly refer to a window of roughly 20–40 milliseconds. [6–8] For students: this is closely related to the concept behind the R-on-T phenomenon—a ventricular premature beat falling on the T wave, when repolarisation is vulnerable. In commotio cordis, however, the initiating stimulus is the chest impact; an actual R-on-T tracing is not required to make the clinical diagnosis, and no such tracing has been publicly documented in de Miguel’s case. The correct conceptual chain is: chest impact over the heart → mechanical activation of cardiac tissue during vulnerable repolarisation → VF → loss of cardiac output → collapse. Why is a seemingly ordinary impact dangerous? Three elements must coincide: location, timing and impact characteristics. A blow directly over the precordium is particularly relevant. It has to arrive during a tiny part of the electrical cycle. The shape, speed and compliance of the impacting object can also affect the risk. Baseballs, softballs, lacrosse balls and hockey pucks have featured prominently in published cases, but footballs and player-to-player collisions have also been reported. [5–7] Young athletes are disproportionately represented, partly because a younger chest wall is more compliant. That does not mean adults are immune. Equally, an especially violent collision may create structural thoracic injury—something that demands assessment on its own and must not automatically be labelled classical commotio cordis. [6,8] Sudden cardiac arrest is not the same as a heart attack Here is the viva trap. Cardiac arrest describes the sudden failure of effective circulation. Sudden cardiac death describes a fatal outcome after a cardiac event. Myocardial infarction is injury caused by myocardial ischaemia, usually from coronary artery obstruction. They are not synonyms. In commotio cordis, the initial lethal event is typically VF: the ventricles quiver instead of contracting productively. Cerebral perfusion drops to nearly zero, and the person collapses. Hypoxic-ischaemic brain injury may develop if circulation cannot be restored promptly. An athlete can appear perfectly fit immediately before this happens. [5–7] Could it have been something else? The differential matters A collapse after chest trauma is a clinical emergency, not a retrospective diagnosis from a video. Other possibilities include cardiac contusion with arrhythmia, myocardial or chamber rupture, traumatic coronary injury, tension pneumothorax or major vascular injury. In athletes, a coincidental spontaneous arrhythmia from cardiomyopathy or channelopathy must also be considered. Classical commotio cordis is generally a diagnosis supported by the sequence of precordial impact followed immediately by arrest, ideally a documented ventricular arrhythmia, and assessment excluding significant structural injury or another primary cardiac cause. Where the clinical and forensic records are incomplete, uncertainty should remain explicit. [6,8] At the touchline: what actually saves lives? A player collapses after a blow to the chest. Do not spend the first precious seconds debating whether the blow looked severe enough. If the person is unresponsive and is not breathing normally—or is only gasping—activate the emergency response, begin CPR and send immediately for an automated external defibrillator (AED). In India, call 112 for emergency assistance where available. [5,9] For an adult, deliver high-quality compressions at 100–120 per minute, approximately 5–6 cm deep, allowing full recoil and minimising interruptions. Switch on the AED as soon as it arrives, attach the pads to the bare chest as shown on the diagrams, and follow its prompts; do not delay compressions while preparing the device. If VF or pulseless VT is identified, the […]

Medical, Medicine, Medicine classes

The New 2026 Definition of Myocardial infarction Explained

Type 1,2, 3, 4a 4b 4c and type 5 are outdated now   Based on 2026 Fifth Universal Definition of Myocardial Infarction: Primary, Secondary & Procedure-Related MI Explained For years, every cardiology learner memorized MI as type 1, type 2, type 3, type 4a/4b/4c and type 5. In 2026, that numerical framework was replaced by a simpler clinical classification. The Fifth Universal Definition of Myocardial Infarction now groups MI into primary, secondary and procedure-related MI. The big change: Old numerical labels are replaced by three clinical categories: PRIMARY MI, SECONDARY MI and PROCEDURE-RELATED MI. Why did the definition change? The older type-based system was scientifically useful but became difficult to apply consistently, particularly when ischemia occurred during another acute illness, when the coronary mechanism was not atherothrombosis, or after PCI or cardiac surgery. The 2026 ESC/ACC/AHA/WHF document shifts the emphasis from memorizing numbers to identifying the clinical mechanism. The new three-part MI classification 1. Primary myocardial infarction Primary MI is a spontaneous MI caused by a primary acute coronary pathology. Importantly, it is broader than the old type 1 atherothrombotic concept. It can include acute coronary atherothrombosis as well as spontaneous coronary artery dissection, coronary embolism, coronary vasospasm and certain late stent/graft failures that behave as new coronary disease rather than immediate procedural complications. Think: the coronary artery itself has developed an acute primary problem. 2. Secondary myocardial infarction Secondary MI occurs when another acute condition creates a myocardial oxygen supply-demand imbalance and objective evidence supports infarction. Examples may include profound anemia, severe hypoxemia, shock, sustained tachyarrhythmia or marked hypertension in the appropriate clinical context. The distinction from myocardial injury remains crucial. Troponin elevation alone does not equal MI. There must be evidence that acute myocardial ischemia is responsible for the injury. Think: the heart is suffering because another acute illness has upset oxygen supply versus demand. 3. Procedure-related myocardial infarction Procedure-related MI is an infarction occurring as a complication of a percutaneous or surgical cardiac procedure. The new framework aims to use clinically meaningful, objective criteria rather than maintaining multiple numerical subtypes. The document distinguishes genuine procedure-related MI from isolated biomarker release after a procedure. Think: the infarction is directly linked to a cardiac procedure and has evidence of a coronary complication plus new myocardial damage. So what happened to old Type 3 MI? The term “type 3 MI” has been removed. When sudden cardiac death is believed to be due to MI but biomarker testing is unavailable, the event should be classified using the new clinical framework — primary, secondary or procedure-related — based on the setting and available clinical or post-mortem evidence. What about troponin? Troponin remains central, but the 2026 document sharpens the distinction between myocardial injury and myocardial infarction. Myocardial injury is defined by cardiac troponin above the 99th percentile upper reference limit. Acute injury requires a dynamic rise and/or fall. To diagnose MI, the troponin pattern must be accompanied by evidence of acute myocardial ischemia. High-yield rule: Troponin elevation = myocardial injury. Troponin elevation + evidence of acute ischemia = myocardial infarction. Sex-specific troponin thresholds receive more emphasis The Fifth Universal Definition supports sex-specific 99th percentile upper reference limits for cardiac troponin where validated assays provide them. The rationale is to reduce systematic under-recognition of myocardial injury and MI in women when a single universal threshold is used. MINOCA has also changed The document updates the terminology around MINOCA to “myocardial injury with non-obstructive coronary arteries,” emphasizing that a non-obstructive angiogram is a starting point for investigation rather than a final mechanism. Further testing may identify infarction, myocarditis, Takotsubo syndrome or another cause of injury. Old versus new: rapid revision table Older framework 2026 framework Core idea Type 1 MI Primary MI Spontaneous acute coronary pathology Type 2 MI Secondary MI Supply-demand imbalance due to another acute condition Type 3 MI Removed as a separate label Classify by clinical setting if MI likely caused death Type 4 / 5 MI Procedure-related MI Complication of PCI or cardiac surgery with objective evidence What changes for exam preparation? Do not rely only on the old numerical labels if a question explicitly asks about the 2026 Fifth Universal Definition. Primary MI is broader than old type 1 MI; it includes acute coronary mechanisms beyond atherothrombosis. Secondary MI is supply-demand imbalance caused by another acute condition. Procedure-related MI replaces the old type 4/5 structure for contemporary classification. Type 3 MI is no longer a separate category. Always distinguish myocardial injury from infarction: ischemia is the deciding concept. Frequently Asked Questions Are Type 1, 2, 3, 4 and 5 MI completely “wrong” now? They belong to the older Fourth Universal Definition framework. The 2026 Fifth Universal Definition replaces the numerical clinical classification with primary, secondary and procedure-related MI. Does every elevated troponin mean MI? No. Elevated troponin means myocardial injury. MI requires acute myocardial injury plus evidence of acute ischemia. What replaces Type 2 MI? Secondary myocardial infarction. What replaces Type 4 and Type 5 MI? Procedure-related myocardial infarction. What is the easiest memory trick? Primary = coronary problem. Secondary = another acute illness creates supply-demand imbalance. Procedure-related = complication of PCI or cardiac surgery.   Authoritative Sources American Heart Association — Fifth Universal Definition of Myocardial Infarction (2026) European Heart Journal — Fifth Universal Definition of Myocardial Infarction (2026) American College of Cardiology — summary of the 2026 Universal Definition   Medical disclaimer: This article is for medical education and does not replace individualized diagnosis or treatment decisions.

Medical, Medicine, Medicine classes

Pirtobrutinib Moves to First-Line Therapy

A drug that entered the CLL story as a rescue option after prior BTK therapy has now crossed a major line: pirtobrutinib is now FDA-approved for previously untreated CLL/SLL in adults without a known 17p deletion. The October 2, 2026 approval is based on the phase 3 BRUIN CLL-313 trial and makes the non-covalent BTK inhibitor relevant at the very start of the treatment pathway. Bottom line: Pirtobrutinib is no longer only a later-line CLL drug. In the newly approved population, it can be used as first-line therapy, and the phase 3 trial showed a marked progression-free survival advantage over bendamustine plus rituximab.   What exactly did the FDA approve? On October 2, 2026, the U.S. FDA approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known deletion of chromosome 17p. The approval was supported by BRUIN CLL-313, a randomized open-label phase 3 study. This wording matters. The approval is not a blanket “all untreated CLL” label. The pivotal trial excluded patients with known del(17p), a biologically high-risk group in which treatment selection remains especially dependent on molecular risk and contemporary guideline pathways. BRUIN CLL-313: the result students and clinicians should remember Population: 282 adults with previously untreated CLL/SLL and no known del(17p). Intervention: pirtobrutinib given until disease progression or unacceptable toxicity. Comparator: bendamustine plus rituximab for six cycles. Primary efficacy endpoint: progression-free survival assessed by independent review. At an estimated median PFS follow-up of 28 months, median PFS was not estimable in the pirtobrutinib arm versus 33.5 months with bendamustine-rituximab. Hazard ratio for progression or death: 0.20 (95% CI 0.11–0.37; p<0.0001) in the FDA summary. Exam memory line: BRUIN CLL-313 = untreated CLL/SLL, no known del(17p), pirtobrutinib versus bendamustine-rituximab, major PFS benefit. Why is pirtobrutinib different from older BTK inhibitors? Ibrutinib, acalabrutinib and zanubrutinib are covalent BTK inhibitors. They bind irreversibly to BTK at cysteine 481. Pirtobrutinib is a highly selective, reversible non-covalent BTK inhibitor. It can inhibit BTK without depending on that covalent C481 bond, which is one reason it became important in patients whose disease had progressed after a covalent BTK inhibitor. The biological concept is high yield: resistance to covalent BTK inhibition can emerge through changes in BTK itself or in downstream signaling. A non-covalent inhibitor uses a different binding strategy and can retain activity in some settings in which a prior covalent inhibitor has failed. Does this mean chemotherapy is finished in CLL? The direction of travel is clear: modern CLL management is increasingly built around targeted therapy rather than traditional chemoimmunotherapy. However, “chemotherapy is dead” is too absolute. Treatment still depends on age, comorbidity, disease genetics, prior therapy, drug availability, patient preference, duration of therapy and regional guidelines. What the new approval does show is how rapidly CLL is moving toward pathway-directed therapy. A non-covalent BTK inhibitor has now beaten a classic bendamustine-rituximab regimen in a first-line randomized study in the approved population. What should be checked before treatment? Confirm the diagnosis and indication for starting therapy; asymptomatic early CLL is often observed rather than treated immediately. Risk-stratify with FISH/cytogenetics and TP53 assessment, particularly because del(17p)/TP53-aberrant disease changes the treatment conversation. Review previous cardiovascular history, bleeding risk, infection history, concomitant medicines and drug interactions. Discuss continuous versus time-limited approaches and patient preferences where alternatives exist. Important adverse effects and practical cautions As with other agents in the BTK pathway, clinicians should remain alert to infection, cytopenias, bleeding, rhythm disturbances and other treatment-emergent toxicities described in the prescribing information. The exact risk profile is not identical across BTK inhibitors, and treatment choice should not be made by mechanism alone. Do not overgeneralize: A new indication does not mean pirtobrutinib is automatically the best first-line choice for every patient with CLL. Molecular risk, co-morbidity, competing regimens, guideline updates and access still matter. Why this update matters for NEET PG / INI-CET / FMGE learners Know the class: pirtobrutinib = non-covalent (reversible) BTK inhibitor. Know the disease: CLL/SLL. Know the 2026 first-line update: previously untreated adults without known del(17p). Know the trial: BRUIN CLL-313. Do not confuse pirtobrutinib with covalent BTK inhibitors such as ibrutinib, acalabrutinib and zanubrutinib. Frequently Asked Questions Is pirtobrutinib a first-line CLL drug now? Yes. In October 2026 the FDA approved it for adults with previously untreated CLL/SLL without a known 17p deletion. Is pirtobrutinib a covalent BTK inhibitor? No. It is a reversible, non-covalent BTK inhibitor. What trial supported the first-line approval? BRUIN CLL-313, which compared pirtobrutinib with bendamustine plus rituximab in previously untreated CLL/SLL without known del(17p). Does this approval include known del(17p) disease? The newly approved first-line population specified no known 17p deletion. High-risk del(17p)/TP53-aberrant disease should be managed according to dedicated contemporary pathways. Can asymptomatic CLL be treated just because a new drug is available? No. Treatment is started for accepted clinical indications; many patients with early asymptomatic CLL remain under active surveillance.   Authoritative Sources S. FDA — Pirtobrutinib approval for previously untreated CLL/SLL (Oct 2, 2026) gov — BRUIN CLL-313 (NCT05023980) Medical disclaimer: This article is for medical education and does not replace individualized diagnosis or treatment decisions.

Medical, Medicine, Medicine classes

A PCSK9 Inhibitor in a Tablet? Meet Enlicitide, the New Oral Cholesterol Drug

For years, there was an easy examination question: “What is the major disadvantage of PCSK9 inhibitors?” One obvious answer was: they are injectable. Not anymore. On July 17, 2026, the US FDA approved enlicitide, marketed as Lipfendra, making it the first FDA-approved oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). In the pivotal clinical program, oral enlicitide produced roughly 56–59% placebo-adjusted reductions in LDL cholesterol at 24 weeks. For a once-daily tablet, that number deserves attention. HIGH-YIELD ONE-LINER: Enlicitide = first oral PCSK9 inhibitor that lowers LDL-C by 65%. WOW!   First, revise PCSK9 in 30 seconds The liver removes circulating LDL cholesterol using LDL receptors. After an LDL particle binds its receptor, the complex is internalized into the hepatocyte. Normally, the LDL receptor can be recycled back to the hepatocyte surface and used again. PCSK9 binds LDL receptors and promotes their degradation. ↑ PCSK9 → ↓ LDL receptors → ↑ circulating LDL-C Block PCSK9 → ↑ recycled LDL receptors → ↑ LDL clearance → ↓ LDL-C That is why PCSK9 became such an attractive therapeutic target. But didn’t we already have PCSK9 drugs? Yes. Alirocumab and evolocumab are monoclonal antibodies targeting PCSK9 and are administered subcutaneously. Inclisiran approaches the pathway differently: it uses small-interfering RNA to reduce hepatic PCSK9 synthesis and is also injectable. The conceptual change with enlicitide is simple: PCSK9 lowering has entered the tablet era. How effective is enlicitide? The FDA approval was supported by randomized, double-blind, placebo-controlled studies in adults with hypercholesterolemia receiving background lipid-lowering therapy. The primary efficacy measure was percentage change in LDL-C at week 24. Population Approx. baseline LDL-C Placebo-adjusted LDL-C reduction at week 24 ASCVD/high cardiovascular risk 96 mg/dL ~56% Heterozygous familial hypercholesterolemia 119 mg/dL ~59% These are substantial LDL reductions and explain why an oral PCSK9 inhibitor has generated considerable clinical interest. The CORALreef story In the Phase 3 CORALreef Lipids study, nearly all participants were receiving statins. At week 24, LDL-C fell markedly with enlicitide while remaining essentially unchanged in the placebo group. Enlicitide also reduced non-HDL cholesterol, apolipoprotein B and lipoprotein(a). The key teaching point is that enlicitide was not developed simply as a replacement for statins in untreated patients. It is a potent additional LDL-lowering option for patients who remain above their recommended LDL level despite background therapy. How does it compare with other oral non-statin drugs? The CORALreef AddOn study provided a useful short-term comparison in statin-treated patients whose LDL remained above target. At day 56, the reported mean LDL-C reductions were approximately: Treatment Approx. LDL-C reduction Enlicitide 65% Ezetimibe 28% Bempedoic acid 6% Bempedoic acid + ezetimibe 37% These are lipid-efficacy comparisons over a relatively short period, not comparisons of cardiovascular outcomes. They nevertheless illustrate the potency of oral PCSK9 inhibition. Does enlicitide replace statins? No. Statins remain foundational therapy for LDL lowering and cardiovascular risk reduction in appropriate patients. The more useful clinical question is what to add when statin therapy does not lower LDL sufficiently, or when treatment needs to be individualized because of tolerance, risk, access or other clinical considerations. Depending on the patient, non-statin options may include ezetimibe, bempedoic acid and PCSK9-directed therapies. Why 2026 is a big year for LDL management The 2026 ACC/AHA dyslipidemia guideline also updated the way clinicians think about lipid management, including explicit LDL-C goals and use of PREVENT-ASCVD equations for primary-prevention risk assessment. Borderline/intermediate-risk primary prevention: LDL-C <100 mg/dL High-risk primary prevention: LDL-C <70 mg/dL Very-high-risk ASCVD: LDL-C <55 mg/dL Very-high-risk ASCVD → think LDL-C <55 mg/dL. The guideline also emphasizes measuring lipoprotein(a), or Lp(a), at least once in adulthood. Together, the new guideline and the arrival of an oral PCSK9 inhibitor make lipid management one of the most important cardiovascular update areas of 2026. Is enlicitide safe? Across the major studies, overall adverse-event rates were broadly comparable between enlicitide and placebo. Reported adverse reactions included symptoms such as diarrhea and dizziness in relevant study populations. As with any newly introduced therapy, prescribing should follow the approved product information and the patient’s individual clinical context. A new drug should not be prescribed merely because an LDL value is elevated. Absolute cardiovascular risk, LDL level, prior therapy, tolerability, comorbidities and current guideline recommendations remain central. The limitation every doctor should understand Enlicitide has demonstrated powerful LDL lowering. But lowering LDL in a lipid-efficacy trial and directly demonstrating fewer myocardial infarctions, strokes or cardiovascular deaths are not identical endpoints. The pivotal studies established strong lipid effects. Long-term cardiovascular outcome evidence will be important in defining the drug’s ultimate place in preventive cardiology. The scientifically correct message today is: enlicitide markedly lowers LDL; the magnitude of its eventual cardiovascular-outcome benefit should be judged from dedicated outcome evidence. NEET-PG / INI-CET / FMGE Exam Box A patient with hypercholesterolemia is prescribed the first FDA-approved oral inhibitor of PCSK9. Which drug has been prescribed? Inclisiran Evolocumab Enlicitide Alirocumab Answer: C. Enlicitide Make these associations automatic: Enlicitide → oral PCSK9 inhibitor Evolocumab / Alirocumab → monoclonal antibodies against PCSK9 Inclisiran → siRNA → decreases hepatic PCSK9 synthesis The bigger story This is not simply another cholesterol tablet. For years, PCSK9-directed treatment meant an injection. Enlicitide changes that practical assumption. Whether oral administration substantially expands PCSK9 use will depend on cardiovascular outcome evidence, long-term safety, cost, availability and real-world adherence. But one fact has already changed: PCSK9 inhibition is no longer an injection-only strategy. And that is precisely the kind of update that separates current clinical medicine from an outdated textbook. Keep Hammering. Frequently Asked Questions What is the first oral PCSK9 inhibitor? Enlicitide (Lipfendra) is the first FDA-approved oral PCSK9 inhibitor. It was approved in July 2026 for adults with hypercholesterolemia, including HeFH. How much does enlicitide lower LDL cholesterol? Pivotal studies reported placebo-adjusted LDL-C reductions of roughly 56% at week 24 in an ASCVD/high-risk population and roughly 59% in patients with HeFH. Is enlicitide an injection? No. Enlicitide is an oral once-daily therapy, distinguishing it from previously approved injectable PCSK9-directed treatments. […]

INICET, Medical, Medicine, Medicine classes, NExT, NExT Exam

FDA Approves First Oral Drug for Dermatomyositis

Brepocitinib (Lisraya) Explained: Mechanism, VALOR Trial, Dose, Safety & Exam Pearls By Dr Deepak Marwah  |  Marwah Medicine A major change has arrived in dermatomyositis treatment. On August 27, 2026, the US FDA approved brepocitinib (Lisraya) tablets for adults with dermatomyositis, making it the first FDA-approved oral treatment specifically indicated for adult dermatomyositis. HIGH-YIELD ONE-LINER Brepocitinib = oral selective TYK2-JAK1 inhibitor → adult dermatomyositis. For medical students, that one line may be enough to answer a future NEET-PG, INI-CET or FMGE update question. For clinicians, however, the story is more interesting: the Phase 3 VALOR trial showed meaningful improvement in overall dermatomyositis activity, skin disease, physical function and glucocorticoid tapering with the 30-mg dose. Why this approval matters Dermatomyositis is a systemic autoimmune inflammatory myopathy. The classic teaching focuses on proximal muscle weakness, heliotrope rash and Gottron papules, but clinically the disease may involve skin, muscle, joints, lungs and other organs. Treatment has traditionally relied heavily on glucocorticoids and other immunomodulatory therapies, many used off-label. A specifically approved oral targeted therapy therefore represents an important change in the treatment landscape. What exactly is brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1. These kinases participate in intracellular cytokine signaling pathways involved in immune activation and inflammation. Think of the pathway as: Cytokine signal → JAK/TYK signaling → inflammatory gene signaling → immune-mediated tissue injury. By inhibiting TYK2 and JAK1, brepocitinib modifies several inflammatory signaling pathways implicated in dermatomyositis. The study behind the approval: VALOR The pivotal evidence came from the Phase 3 VALOR trial, a double-blind randomized placebo-controlled study involving 241 adults with dermatomyositis. Participants received brepocitinib 30 mg once daily, brepocitinib 15 mg once daily, or placebo for 52 weeks. Background standard therapies were continued and glucocorticoids were tapered. What did the trial show? Group Mean Total Improvement Score at Week 52 Brepocitinib 30 mg 46.5 Brepocitinib 15 mg 37.5 Placebo 31.2 The 30-mg dose was significantly superior to placebo for the primary endpoint. Importantly, brepocitinib 30 mg was also superior across all nine key secondary endpoints, including skin disease activity, systemic glucocorticoid tapering and functional disability. Improvements in some outcomes were observed as early as week 4. It was not just about muscle enzymes One of the clinically attractive aspects of the VALOR results is that benefit was not restricted to a laboratory value. Dermatomyositis can produce persistent and troublesome cutaneous disease even when muscle manifestations are less dramatic. The 30-mg dose demonstrated improvement across clinically relevant domains including skin activity and physical function. The steroid-sparing angle Long-term glucocorticoid exposure carries substantial toxicity, including diabetes, osteoporosis, infection risk, cataracts, hypertension and weight gain. In VALOR, improvement with brepocitinib 30 mg was accompanied by greater glucocorticoid tapering. This makes the result clinically more meaningful than a change in a single disease marker. Does this replace steroids? No. The approval should not be interpreted as meaning that every newly diagnosed patient can simply replace conventional therapy with one tablet. Dermatomyositis is heterogeneous. Treatment decisions still depend on the severity and pattern of muscle disease, dysphagia, respiratory involvement, interstitial lung disease, skin disease, autoantibody profile, malignancy evaluation, previous treatment response and patient-specific risks. Also remember an important trial detail: standard therapies were continued while glucocorticoids were tapered. Brepocitinib adds a new targeted option; it does not erase the need for individualized specialist management. Dose: the number worth remembering The FDA-approved Lisraya tablet contains brepocitinib 30 mg, administered orally once daily for adults with dermatomyositis. Safety: oral does not mean casual Brepocitinib is a potent immunomodulatory therapy. In VALOR, serious infections occurred more frequently with brepocitinib 30 mg than with placebo (10% versus 1%). The FDA prescribing information contains important warnings and precautions, including serious infections, malignancy, major adverse cardiovascular events and thrombosis. Common adverse reactions reported in the FDA medication information include upper respiratory tract infections, headache, fatigue, urinary tract infection, nausea, bronchitis, arthralgia, diarrhea, back pain, falls, influenza and acne. Clinical message: “Oral” should never be confused with “low-risk.” Appropriate patient selection, screening and monitoring remain essential. What should medical students remember? Drug: Brepocitinib Trade name: Lisraya Route: Oral, once daily Dose: 30 mg once daily Mechanism: Selective TYK2-JAK1 inhibitor Indication: Dermatomyositis in adults FDA approval: August 27, 2026 Key trial: VALOR Potential exam question A patient with dermatomyositis is started on a newly FDA-approved oral therapy that selectively inhibits TYK2 and JAK1. Which drug is most likely being prescribed? Answer: Brepocitinib (Lisraya). The bigger lesson: targeted therapy is entering myositis For years, dermatomyositis was taught through its memorable clinical signs: heliotrope rash, Gottron papules and proximal muscle weakness. Those remain fundamental. But modern medicine increasingly asks a second question: which molecular pathways are driving the disease, and can those pathways be targeted? Brepocitinib represents that transition from broad immunosuppression toward more targeted immune modulation. Its ultimate place in treatment algorithms will continue to evolve with real-world experience, longer-term safety data, accessibility and cost. But the 2026 approval itself is already an important milestone in dermatomyositis therapy. Frequently Asked Questions What is the new oral drug for dermatomyositis? Brepocitinib, marketed as Lisraya, was FDA-approved in August 2026 for the treatment of dermatomyositis in adults. What is the mechanism of brepocitinib? Brepocitinib is an oral selective inhibitor of TYK2 and JAK1, modifying cytokine signaling involved in inflammatory and autoimmune pathways. What is the dose of brepocitinib for dermatomyositis? The FDA-approved Lisraya dose is 30 mg orally once daily. Is brepocitinib a JAK inhibitor? Yes. Brepocitinib selectively inhibits TYK2 and JAK1. Is brepocitinib better than steroids for dermatomyositis? The treatments should not be reduced to a simple either-or comparison. In VALOR, background standard therapies were continued while glucocorticoids were tapered. The 30-mg brepocitinib group showed clinical benefit and greater glucocorticoid tapering. What is the most important safety concern? Serious infection risk is important. The FDA label also contains warnings and precautions regarding malignancy, major adverse cardiovascular events and thrombosis. What should NEET-PG and INI-CET students remember? Brepocitinib → oral TYK2-JAK1 inhibitor → adult dermatomyositis. Remember the 30-mg once-daily dose […]

Scroll to Top